Enhancement of Therapeutic Effects of Recombinant Interleukin 2 on a Transplantable Rat Fibrosarcoma by the Use of a Sustained Release Vehicle, Pluronic Gel

Cancer Research

Volumn 47, Issue 1, 1986, Pages 37-41

  Morikawa, Kiyoshi ^a   Okada, Futoshi ^a   Hosokawa, Masuo ^a   Kobayashi, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG VEHICLE; INTERLEUKIN 2; POLOXAMER;

ANIMAL EXPERIMENT; DRUG COMPARISON; DRUG EFFICACY; FIBROSARCOMA; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSTAINED RELEASE PREPARATION; THERAPY; TOPICAL DRUG ADMINISTRATION;

ANIMAL; CYTOTOXICITY, IMMUNOLOGIC; DELAYED-ACTION PREPARATIONS; DRUG SYNERGISM; FEMALE; FIBROSARCOMA; GELS; INTERLEUKIN-2; LYMPH NODES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; POLOXALENE; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED STRAINS; RECOMBINANT PROTEINS; SPLEEN; VEHICLES;

EID: 0023112413     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Smith, K. A. T-cell growth factor. Immunol. Rev., 51: 337-357, 1980.
2. Hersey, P., Bindon, C., Edwards, A., Murray, E., Phillips, G., and McCarthy, W. H. Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2. Int. J. Cancer, 28: 695-703, 1981.
3. Vose, B. M., and Bonnard, G. D. Specific cytotoxicity against autologous tumor and proliferative responses of human lymphocytes grown in interleukin-2. Int. J. Cancer, 29: 33-39, 1982.
4. Wagner, H., Hardet, C., Heeg, K., Rollinghoff, M., and Pfizenmaier, K. T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice. Nature (Lond.), 284: 278-280, 1980.
5. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A. The lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med., 155: 1823-1841, 1982.
6. augments 6. Henney, C. S., Kuribayashi, K., Kern, D. E., and Gillis, S. Interleukin 2 natural killer cell activity. Nature (Lond.), 291: 335-338, 1981.
7. Hefeneider, S. H., Conlon, P. J., Henney, C. S., and Gillis, S. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J. Immunol., 130: 222-227, 1983.
8. Rosenberg, S. A., Mule, J. J., Spiess, P. J., Reichert, C. M., and Schwarz, S. L. Regression of established pulmonary metastasis and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J. Exp. Med., 161: 1169-1188, 1985.
9. Claeson, A. E., Derante, A. J. S., Kupiec-Weglinski, J. W., Williams, J. N., Wary, B. S., Strom, T. B., and Tilney, N. L. Restoration of allograft responsiveness in B rats by interleukin 2 and/or adherent cells. J. Immunol., 129: 252-259, 1982.
10. Merluzzi, U. J., Walker, M. M., and Faanes, R. B. Inhibition of cytotoxic T-cell clonal expansion by cyclophosphamide and the recovery of cytotoxic T-lymphocyte precursors by supernatants from mixed-lymphocyte cultures. Cancer Res., 41: 3663-3665, 1981.
11. Stotter, H., Ruede, E., and Wagner, H. T-cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice. Eur. J. Immunol., 10: 719-722, 1980.
12. Bubenik, J., Indrovà, M., Perlmann, P., Berzins, K., Mach, O., Kraml, J., and Toulcova, A. Tumor inhibitory effects of TCGF/IL-2/containing preparations. Cancer Immunol. Immunother., 19: 57-61, 1985.
13. Pizza, G., Sererini, G., Menniti, D., De Vinci, C., and Corrado, F. Tumor regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report. Int. J. Cancer, 34: 359-367, 1984.
14. Cheever, M. A., Greenberg, P. D., Fefer, A., and Gillis, S. Augmentation of the antitumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J. Exp. Med., 155: 968-980, 1982.
15. Donohue, J. H., Rosenstein, M., Chang, A. E., Lotze, M. T., Robb, R. J., and Rosenberg, S. A. The systemic administration of purified interleukin-2 enhances the ability of sensitized murine lymphocytes lines to culture a disseminated syngeneic lymphoma. J. Immunol., 132: 2123-2128, 1984.
16. Mazumder, A., and Rosenberg, A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastasis by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J. Exp. Med., 159: 495-507, 1984.
17. Mule, J. J., Shu, S., Schwartz, S. L., and Rosenberg, S. A. Successful adoptive immunotherapy of established pulmonary metastases of multiple sarcomas with lymphokine-activated killer cells and recombinant interleukin 2. Science (Wash. DC), 225: 1487-1489, 1984.
18. Donohue, J. H., and Rosenberg, S. A. The fate of interleukin-2 after in vivo administration. J. Immunol., 130: 2203-2208, 1983.
19. Muhlradt, P. F., and Opitz, H. G. Clearance of interleukin 2 from the blood of normal and T-cell-depleted mice. Eur. J. Immunol., 12: 983-985, 1982.
20. Cheever, M. A., Thompson, J. A., Kern, D. E., and Greenberg, P. D. Interleukin 2 (IL-2) administered in vivo: influence of IL-2 route and cell growth. J. Immunol., 134: 3895-3900, 1985.
21. Chang, A. E., Hyatt, C. L., and Rosenberg, S. A. Systemic administration of recombinant human interleukin-2 in mice. J. Biol. Response Modif., 3: 561-572, 1984.
22. Cheever, M. A., Greenberg, P. D., Irle, C., Thompson, J. A., Urdal, D. L., Mochizuki, D. Y., Henney, C. S., and Gillis, S. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J. Immunol., 132: 2259-2265, 1985.
23. Nishimura, T., Togashi, Y., Goto, M., Yugi, H., Uchiyama, Y., and Hashimoto, Y. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol. Immunother., 21: 12-18, 1986.
24. Schmolka, I. R. Artificial skin 1. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res., 6: 571-582, 1972.
25. Asahi Denka Kogyo Co. Pluronic and Tetronic, Publication No. 04, 1981.
26. Miyazaki, S., Takeuchi, S., Yokouchi, C., and Takada, M. Pluronic F-127 gels as a vehicle for topical administration of anticancer agents. Chem. Pharm. Bull., 32: 4205-4208, 1984.
27. Devos, R., Plaetinck, G., Cheroutre, H., Simons, G., Degrave, W., Tayernier, J., Remaut, E., and Fiers, W. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucl. Acids Res., 11: 4307-4323, 1983.
28. Gillis, S., Ferm, M. M., Ou, W., and Smith, K. A. T cell growth factor parameters of production and a quantitative microassay for activity. J. Immunol., 120: 2027-2032, 1978.
29. Morikawa, K., Hosokawa, M., Hamada, J., Sugawara, M., and Kobayashi, H. Host-mediated therapeutic effects produced by appropriately timed administration of bleomycin on a rat fibrosarcoma. Cancer Res., 45: 1502-1506, 1985.
30. Mokyr, M. B., Hengst, J. C. D., Przepiorka, D., and Dray, S. Augmentation antitumor cytotoxicity of MOPC-315 tumor bearer spleen cells by depletion of DNP-adherent cells prior to in vitro immunization. Cancer Res., 39: 3928-3934, 1979.
31. Handa, K., Suzuki, R., Matsui, H., Shimizu, Y., and Kumagai, K. Natural killer (NK) cells as a responder to interleukin 2 (IL-2). II. IL-2 induced interferon-γ production. J. Immunol., 130: 988-992, 1983.
32. Kawase, I., Brooks, C. G., Kuribayashi, K., Olabuenaga, S., Newman, W., Gillis, S., and Henney, C. S. Interleukin 2 induces interferon production: participation of macrophages and NK-like cells. J. Immunol., 131: 288-292, 1983.
33. Chen-Chow, P. C., and Frank, S. G. In vitro release of lidocaine from pluronic F-127 gels. Int. J. Pharmacol., 8: 89-99, 1981.
34. Rassing, J., and Attwood, D. Ultrasonic velocity and light-scattering studies on the polyoxyethylene-polyoxypropylene copolymer pluronic F-127 in aqueous solution. Int. J. Pharmacol., 13: 47-55, 1983.
35. Silk, M., and Sigman, E. Effect of pluronic F-68 on the development of tumor metastasis. Cancer (Phila.), 29: 171-172, 1972.